[u'-----BEGIN PRIVACY-ENHANCED MESSAGE-----\nProc-Type: 2001,MIC-CLEAR\nOriginator-Name: webmaster@www.sec.gov\nOriginator-Key-Asymmetric:\n MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen\n TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB\nMIC-Info: RSA-MD5,RSA,\n QdfyoI2WHu+MeljNlsnpMjxCPm3Ohx82nEL5eQLRKBLMYYDMv2nrl3G2Es+i86sg\n 9CI3K5SISKtJxtqUuRYbvw==\n\n', u'0001104659-04-027750.txt : 20040915\n', u'0001104659-04-027750.hdr.sgml : 20040915\n', u'20040915172326\nACCESSION NUMBER:\t\t0001104659-04-027750\nCONFORMED SUBMISSION TYPE:\t8-K\nPUBLIC DOCUMENT COUNT:\t\t3\nCONFORMED PERIOD OF REPORT:\t20040915\nITEM INFORMATION:\t\tResults of Operations and Financial Condition\nITEM INFORMATION:\t\tFinancial Statements and Exhibits\nFILED AS OF DATE:\t\t20040915\nDATE AS OF CHANGE:\t\t20040915\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tVALENTIS INC\n\t\tCENTRAL INDEX KEY:\t\t\t0000932352\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tBIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]\n\t\tIRS NUMBER:\t\t\t\t943156660\n\t\tSTATE OF INCORPORATION:\t\t\tDE\n\t\tFISCAL YEAR END:\t\t\t0630\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\t8-K\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t000-22987\n\t\tFILM NUMBER:\t\t041032353\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t863A MITTEN RD\n\t\tCITY:\t\t\tBURLINGAME\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t94010\n\t\tBUSINESS PHONE:\t\t6506971900\n\n\tMAIL ADDRESS:\t\n\t\tSTREET 1:\t\t863A MITTEN ROAD\n\t\tCITY:\t\t\tBURLINGAME\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t94010\n\n\tFORMER COMPANY:\t\n\t\tFORMER CONFORMED NAME:\tMEGABIOS CORP\n\t\tDATE OF NAME CHANGE:\t19960716\n', u'\n', u'\n', u'8-K\n', u'1\n', u'a04-10593_18k.htm\n', u'8-K\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'SECURITIES AND EXCHANGE COMMISSION', u'\n', u'\xa0', u'\n', u'Washington D.C. 20549', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'FORM 8-K', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'CURRENT REPORT', u'\n', u'\xa0', u'\n', u'PURSUANT TO SECTION\xa013 OR 15(d) OF', u'\nTHE SECURITIES EXCHANGE ACT OF 1934', u'\n', u'\xa0', u'\n', u'Date of Report: September\xa015, 2004', u'\n', u'(Date\nof Earliest Event Reported)', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'Valentis, Inc.', u'\n', u'(Exact\nName of Registrant as Specified in Its Charter)', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'Delaware', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Commission File:', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'94-3156660', u'\n', u'\n', u'\n', u'\n', u'\n', u'(State\n  or Other Jurisdiction', u'\n  of Incorporation or Organization)', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'0-22987', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(I.R.S.\n  Employer', u'\n  Identification No.)', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'863A Mitten Road', u'\nBurlingame, California', u'\n', u'94010', u'\n', u'(Address\nof Principal Executive Offices)', u'\n', u'\xa0', u'\n', u'(650) 697-1900', u'\n', u'(Registrant\x92s\nTelephone Number, Including Area Code)', u'\n', u'\xa0', u'\n', u'N/A', u'\n', u'(Former\nName or Former Address, if Changed Since Last Report)', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u" SEQ.=1,FOLIO='',FILE='C:\\jms\\ssrinev\\04-10593-1\\task184925\\10593-1-ba.htm',USER='ssriram',CD='Sep 15 07:03 2004' ", u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'ITEM 2.02.', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 ', u'Results of Operations and\nFinancial Condition.', u'\n', u'\xa0', u'\n', u'On September\xa015, 2004,\nValentis, Inc. announced results for its fourth fiscal quarter and fiscal year\nended June\xa030, 2004.\xa0 A copy of the\npress release regarding this announcement is furnished as Exhibit 99.1 to this\nreport.', u'\n', u'\xa0', u'\n', u'ITEM 9.01.', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 ', u'Financial Statements and\nExhibits.', u'\n', u'\xa0', u'\n', u'(c)', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 ', u'Exhibits.', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'Exhibit No.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Description', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'99.1', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Text of Press Release,\n  dated September\xa015, 2004', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'2', u'\n', u'\n', u'\n', u'\n', u'\n', u" SEQ.=1,FOLIO='2',FILE='C:\\jms\\ssrinev\\04-10593-1\\task184925\\10593-1-ba.htm',USER='ssriram',CD='Sep 15 07:03 2004' ", u'\n', u'\n', u'\n', u'\xa0', u'\n', u'SIGNATURE', u'\n', u'\xa0', u'\n', u'Pursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this\nreport to be signed on its behalf by the undersigned hereunto duly authorized.', u'\n', u'\xa0', u'\n', u'Dated:\xa0 September\xa0 15, 2004', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'VALENTIS, INC.', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'By:', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 /s/ JOSEPH A. MARKEY', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 Joseph A. Markey', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0 Senior Director of Finance and\n  Controller (Principal', u'\n  Financial and Accounting Officer)', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'3', u'\n', u'\n', u'\n', u'\n', u'\n', u" SEQ.=1,FOLIO='3',FILE='C:\\jms\\ssrinev\\04-10593-1\\task184925\\10593-1-ba.htm',USER='ssriram',CD='Sep 15 07:03 2004' ", u'\n', u'\n', u'\n', u'\n', u'EX-99.1\n', u'2\n', u'a04-10593_1ex99d1.htm\n', u'EX-99.1\n', u'\n', u'\n', u'EXHIBIT 99.1', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 Valentis,\nInc.', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Valentis,\n  Inc.', u'\n', u'\n', u'\n', u'Investor\n  and Media Inquiries', u'\n', u'\n', u'\n', u'\n', u'\n', u'Joe Markey', u'\n', u'\n', u'\n', u'Jeannine Medeiros', u'\n', u'\n', u'\n', u'\n', u'\n', u'(650) 697-1900 x369', u'\n', u'\n', u'\n', u'(650) 740-8589', u'\n', u'\n', u'\n', u'\n', u'\n', u'markey@valentis.com', u'\n', u'\n', u'\n', u'jmedeiros@aragon-consulting.com', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'VALENTIS\nANNOUNCES FISCAL\xa02004 FINANCIAL RESULTS', u'\n', u'\xa0', u'\n', u'Burlingame, CA, September\xa015,\xa02004', u' - Valentis, Inc. (NASDAQ:VLTS)\ntoday announced fiscal\xa02004 financial results for the fourth quarter and\nfiscal year ended June\xa030,\xa02004.', u'\n', u'\xa0', u'\n', u'Valentis reported a net loss applicable to common stockholders for the\nyear ended June\xa030,\xa02004 of $6.5\xa0million, or\n$0.81\xa0per\xa0basic and diluted share, on revenue of $7.5\xa0million,\ncompared to a net loss applicable to common stockholders of $43.0\xa0million,\nor $13.86\xa0per\xa0basic and diluted share on revenue of $4.0\xa0million\nfor fiscal\xa02003.', u'\n', u'\xa0', u'\n', u'For the quarter ended June\xa030,\xa02004, Valentis recorded a net\nloss applicable to common stockholders of $3.7\xa0million, or $0.33 per basic\nand diluted share, on revenue of $40,000, compared to a net loss applicable to\ncommon shareholders of $2.1\xa0million, or $0.37 per basic and diluted share,\non revenue of $1.3\xa0million, for the quarter ended June\xa030,\xa02003.', u'\n', u'\xa0', u'\n', u'On\nJune\xa030,\xa02004, Valentis had $20.5\xa0million in cash, cash\nequivalents and short-term investments compared to $11.9\xa0million on\nMarch\xa031,\xa02004 and $3.3\xa0million on June\xa030,\xa02003. The\nincrease of $8.6\xa0million and $17.2\xa0million in cash, cash equivalents\nand short-term investments balances for the quarter and the year, respectively,\nreflect a $6.5\xa0million payment from', u'\nALZA\xa0Corporation/Johnson\xa0&\xa0Johnson for', u'\nthe settlement of a lawsuit in July\xa02003, a $10\xa0million financing\ncompleted in January\xa02004 and a $12\xa0million financing completed in\nJune\xa02004 offset by spending to fund the company\x92s operations.', u'\n', u'\xa0', u'\n', u'Research and development expenses for the fiscal year ended\nJune\xa030,\xa02004, remained at the same level on an annual basis as\nfiscal\xa02003 at $10.0\xa0million. For the fourth quarter ended\nJune\xa030,\xa02004, research and development expenses increased to\n$2.6\xa0million from $2.2\xa0million in the corresponding period in\nfiscal\xa02003. The increases were attributable primarily to increased\nclinical trial expenses for the Phase\xa0II Deltavasc\x99 study, which was\ninitiated in July\xa02003, and were partially offset, by decreased expenses\nresulting from staff reductions in October\xa02002.', u'\n', u'\xa0', u'\n', u'General\nand administrative expenses ', u'for the fiscal year ended June\xa030,\xa02004, ', u'decreased to $3.9\xa0million from\n$8.9\xa0million in fiscal\xa02003. General and administrative expenses ', u'for\nthe quarter ended June\xa030,\xa02004, decreased to $1.1\xa0million from\n$1.6\xa0million in the corresponding period in fiscal\xa02003.', u' The decreases were attributable primarily to\ndecreased expenses for professional services resulting from the settlement of a\npatent infringement litigation and staff reductions in October\xa02002.', u'\n', u'\xa0', u'\n', u'For the year ended June\xa030,\xa02003, we recorded\ndividend and deemed dividend charges of approximately $5.9\xa0million related\nto Series\xa0A preferred stock and an adjustment of approximately\n$22.3\xa0million resulting from the reduction in the Series\xa0A preferred\nstock conversion price. These charges and the adjustment were included in the\nnet loss applicable to common stockholders for the fiscal year ended\nJune\xa030,\xa02003.', u'\n', u'\xa0', u'\n', u'Liquidity', u'\n', u'\xa0', u'\n', u'Valentis has received a report from our\nindependent auditors regarding our consolidated financial statements for the\nfiscal year ended June\xa030,\xa02004 that includes an explanatory\nparagraph stating that the financial statements have been prepared assuming\nValentis will continue as a going concern. The explanatory paragraph states the\nfollowing conditions, which raise substantial doubt about our ability to\ncontinue as a going concern: (i)\xa0we have incurred losses since inception,\nincluding a net loss of ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'863A Mitten Road ', u'\xb7', u' Burlingame, CA 94010 ', u'\xb7', u' Tel. (650) 697-1900 ', u'\xb7', u' Fax (650) 652-1990', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u" SEQ.=1,FOLIO='',FILE='C:\\JMS\\asandfo\\04-10593-1\\task185218\\10593-1-ma.htm',USER='asandfo',CD='Sep 15 16:10 2004' ", u'\n', u'\n', u'\xa0', u'\n', u'$6.5\xa0million for the year ended\nJune\xa030,\xa02004, and our accumulated deficit was $213.6\xa0million at\nJune\xa030,\xa02004 and (ii)\xa0we anticipate requiring additional\nfinancial resources to enable us to fund our operations at least through\nJune\xa030,\xa02005.', u'\n', u'\xa0', u'\n', u'Deltavasc\x99\xa0\nPhase\xa0II Clinical Trial', u'\n', u'\xa0', u'\n', u'Deltavasc\x99 is Valentis\x92 lead product for the\ntreatment of patients with the intermittent claudication form of peripheral\narterial disease and is currently in a Phase\xa0II clinical trial. Valentis\nexpects that the results from this Phase\xa0II trial will be available at the\nend of September\xa02004.', u'\n', u'\xa0', u'\n', u'About\nValentis', u'\n', u'\xa0', u'\n', u'Valentis is creating innovative cardiovascular\ntherapeutics. The company begins its product development at the stage of a\nvalidated target and applies its expertise in formulation, manufacturing,\nclinical development and regulatory affairs to create products that fill unmet\nmedical needs. Valentis has a series of technologies that allow the company to\ngenerate novel therapeutics to treat a wide range of diseases. While Valentis\nis focusing its efforts on the development of novel cardiovascular\ntherapeutics, its technologies are being applied by its collaborators for the\ndevelopment of therapeutics to treat a variety of indications including\ninfectious diseases and cancer.', u'\n', u'\xa0', u'\n', u'Additional information about\nValentis can be found at www.valentis.com.', u'\n', u'\n', u'\xa0', u'\n', u'Statements in this press release that are not strictly historical are \x93forward\nlooking\x94 statements as defined in the Private Securities Litigation Reform Act\nof 1995. The words \x93believes,\x94 \x93expects,\x94 \x93intends,\x94 \x93anticipates,\x94 variations\nof such words, and similar expressions identify forward-looking statements, but\ntheir absence does not mean that the statement is not forward-looking.\nForward-looking statements include our expectation that the results from the\nPhase II trial will be available at the end of September\xa02004, that we\nanticipate requiring additional financial resources and our ability to raise\nadditional financial resources, our expectation to continue as a going concern\nand future operating results. These statements are not guarantees of future\nperformance and are subject to certain risks, uncertainties and assumptions\nthat could cause our actual results to differ materially from those projected\nin the forward-looking statement. Factors that could affect Valentis\x92 actual\nresults include uncertainties related to clinical trials, the need for\nadditional capital, the early stage of product development and uncertainties\nrelated to product development. Further, there can be no assurance that\nValentis will be able to develop commercially viable gene based or PEGylated\nbiopharmaceuticals, that any of the company\x92s programs will be partnered with\npharmaceutical partners, that necessary regulatory approvals will be obtained,\nor that any clinical trial, including Valentis\x92 Phase\xa0II Deltavasc\x99 trial,\nwill be successful. Actual results may also differ from those projected in\nforward-looking statements due to risks and uncertainties that exist in\nValentis\x92 operations and business environments. The risks and uncertainties to\nwhich Valentis is subject are described more fully in Part I \x97 Item 1. Business\n\x97 Additional Factors That May Affect Future Results, and elsewhere in the\nValentis Annual Report on Form 10-K for the period ended\nJune\xa030,\xa02004, as filed with the Securities and Exchange Commission.\nForward-looking statements contained in this announcement are made as of this\ndate and will not be updated.', u'\n', u'\n', u'\xa0', u'\n', u'2', u'\n', u'\n', u'\n', u'\n', u" SEQ.=1,FOLIO='2',FILE='C:\\JMS\\asandfo\\04-10593-1\\task185218\\10593-1-ma.htm',USER='asandfo',CD='Sep 15 16:10 2004' ", u'\n', u'\n', u'\xa0', u'\n', u'Valentis, Inc.', u'\n', u'Selected Consolidated Financial\nData', u'\n', u'(in thousands, except per share\namounts)', u'\n', u'\xa0', u'\n', u'Statements of Operations', u'\n', u'(in thousands, except per share amounts)', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Three months ended June 30,', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Year ended June 30,', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2004', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2003', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2004', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2003', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(unaudited)', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'License and\n  milestone revenue', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'1,300', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'7,284', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'3,958', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Other revenue', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'40', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'194', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'40', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'1,300', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'7,478', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'3,958', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Operating\n  expenses:', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Research and\n  development', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2,635', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2,151', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'10,054', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'9,965', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'General and\n  administrative', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'1,123', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'1,603', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'3,912', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'8,859', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Restructuring\n  charges', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'832', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Total operating\n  expenses', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'3,758', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'3,754', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'13,966', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'19,656', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Loss from\n  operations', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(3,718', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'(2,454', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'(6,488', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'(15,698', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Interest income', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'35', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'9', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'90', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'111', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Other income and\n  interest expense, net', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'14', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'394', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(86', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'727', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Net loss', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(3,669', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(2,051', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(6,484', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(14,860', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Deemed Dividend', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(4,972', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'\n', u'\n', u'Adjustment\n  resulting from the reduction in the Series A preferred stock conversion price', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(22,293', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'\n', u'\n', u'Dividends on\n  Preferred Stock', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\x97', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(882', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'\n', u'\n', u'Net loss\n  applicable to common stockholders', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(3,669', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(2,051', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(6,484', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(43,007', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Basic and\n  diluted net loss per share applicable to common shareholders', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(0.33', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(0.37', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(0.81', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'(13.86', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'\n', u'\n', u'Shares used in\n  computing basic and diluted net loss per share', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'10,998', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'5,554', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'8,024', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'3,103', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'Condensed Balance Sheets', u'\n', u'(in\nthousands)', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'June 30, 2004', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'June 30, 2003', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Assets', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Cash, cash equivalents and short-term investments', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'20,450', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'3,290', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Other current assets', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'856', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'829', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Total current assets', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'21,306', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'4,119', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Property and equipment, net', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'79', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'1,511', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Goodwill and other assets', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'506', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'448', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'21,891', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'6,078', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Liabilities and stockholders\x92 equity', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Accounts payable and accruals', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'3,901', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'3,314', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Deferred revenue', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'100', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'175', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Common stock', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'231,444', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'209,659', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'Accumulated deficit', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(213,554', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'(207,070', u'\n', u'\n', u'\n', u')', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'21,891', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'$', u'\n', u'\n', u'\n', u'6,078', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'###', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3', u'\n', u'\n', u'\n', u'\n', u'\n', u" SEQ.=1,FOLIO='3',FILE='C:\\JMS\\asandfo\\04-10593-1\\task185218\\10593-1-ma.htm',USER='asandfo',CD='Sep 15 16:10 2004' ", u'\n', u'\n', u'\n', u'\n', u'GRAPHIC\n', u'3\n', u'g105931maimage002.gif\n', u'GRAPHIC\n', u"\nbegin 644 g105931maimage002.gif\nM1TE&.#=A5`!.`''AX1$1$'!P7EU=75B8F)_?W]M;6U@8&!C8V-T='1V=G9F9F9]?7UPGI[>WN9F9F$A(2;FYN7EY>:FIJ*BHJ?\nMGY^,C(R3DY.4E)2!@8&-C8V>GIZ8F)B2DI*'AX>1D9&", u'MK:VXN+B\\O+RKJZNIJ:FWM[>FIJ:_O[^^OKZS\nML[.BHJ*TM+3-S', u'WP\\/#Q\\?\'HZ.CN[N[S\\_/L[.SR\\O+KZ^O^_O[]_?WJZNK\\_/SG\nMY^?T]/3AX>\'CX^/U]?7W]_?Y^?GX^/CDY.3EY>7IZ>GO[^_Z^OKFYN;[^_OV\nM]O;___\\!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!\nM`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!\nM`@,!`@,!`@,!`@,(_P"_"1Q(L*#!@P@3$BSUADH.`0$`2)08@(,..*84:MS(\nML2/!1#L&3!Q)LB2/4QY3JE08IT-)`AZJR%&$2MBP8HQ\'R-+U.GZ$0`6LBN)_1B9\nM!1G:@LD`H\'S+$', u'`%3NK7KU[!CER[B*(^1TD>2S)\nMN[?OW\\!]0SI1,F6SX,B3*R>)"@7)5"KA+)].G?>W`R//KA10O?MT!-]&)O^`\nMZKT\\\\BKA)PX3ZJQ*)//P>S^3-%\'/4`4`)AF-SQ_`>"02I3#41-"DUQ]\\>QCH\nMC%`+`,#`0)0D@,,14V5QGPS\nMC41!K30)`(U`=4>0PC@)`!Q#L1`H5"VD2(VI!9#_A]=5$CXPT$35#,4E69CT\nMYX)`S$PT!U1Y\'(#6"_%9(1`R$\\$0U0]CO`4?H]_8,M)5$A2&EB+>35#@-W^,\nME`FMEKVE0W5@#"3$2$MT14%?U+DB4#(5D$26!WV5HAP9`P%2DBID1=M7&0=$0L!`U"\'1I0\\:%*-)\\)=`PJG@221KHIY=*L502I\nMX=U*"%1]X4Y`TA!/#WQ$IEW$&)+:G85`POH$`RR!HA(+$2-H5P)V$H*D&1!R"1\nM].*+*["`(DD?6"2Q@K,[#`%#0!\\K%$C>DK$B4>[7,##$&"4444:9OC`0@I/\nM4DC\\)I(2%BR@!CE`@A""X`$;4$`B@-C(#08HD1:D!#L8R(`&+#"!B7!A(Z.@\nMX$0"D9(=\\&8L&G&&"$88/"0)\nM-VP,\\\\`@3F0#@FF#$4G"+[KP:(DD^05=T@1%>Z%E#54LB13(`HPL\\B887?%B\nM;ZY"!#\'RI@E0`849>T.*`:UQC"OQP!M[@P.5T&>.O8E@1XB!Q]]@HR.Z8$4I\n6!DG(0AKRD(A,I"(7R', u'\n', u'\n', u'\n-----END PRIVACY-ENHANCED MESSAGE-----\n']